Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: M. Ramle who wrote (3740)	10/6/1999 11:23:00 AM
From: Biomaven	Read Replies (1) \| Respond to of 10280

Mazen, I really don't think the FTC investigation has anything at all to do with the Claritin II NDA. If they do file this quarter, as has been strongly rumored, it will be an impressive demonstration of just how fast you can move when money is no object and you are dealing with an ICE rather than a new drug. Peter

To: M. Ramle who wrote (3740)	10/6/1999 3:56:00 PM
From: PaulW	Read Replies (2) \| Respond to of 10280

Mazen: There are several investigations by the FTC - the one receiving the most press is the HOE and ADRX agreement. It started awhile ago and ADRX had a press release on it last October. The FDA approved 3 ADRX ANDAs last month. So, I am very confident that it will not have any impact on any SEPR/SGP filing including the son of Clariton or Prozac. Unfortunately, since quarter end, which coincided with an article in USA Today about the HOE and ADRX investigation and an unfounded rumor that a suit was recommended (unfounded according to an ADRX press release), ADRX is down around 25% in the last 4 days. You can look at the news on YAHOO under ADRX and get a feel how ugly it can get. I am long ADRX and SEPR)